
Dec 23 (Reuters) - Sanofi SA SASY.PA:
SANOFI AND REGENERON’S DUPIXENT APPROVED IN JAPAN FOR CHILDREN AGED 6 TO 11 YEARS WITH BRONCHIAL ASTHMA
APPROVAL BASED ON GLOBAL PHASE 3 PROGRAM IN CHILDREN DEMONSTRATING DUPIXENT SIGNIFICANTLY REDUCED EXACERBATIONS
DUPIXENT REDUCES ASTHMA EXACERBATIONS BY 54%-65%